Cover Image
市場調查報告書

血友病:市場預測與分析

Hemophilia disease forecast and market analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 365167
出版日期 內容資訊 英文 473 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血友病:市場預測與分析 Hemophilia disease forecast and market analysis to 2035
出版日期: 2017年03月19日 內容資訊: 英文 473 Pages
簡介

本報告提供血友病治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:血友病

  • 摘要整理
  • 市場概要·趨勢
  • 調查手法·市場定義
  • Advate
  • Adynovate
  • Alprolix
  • BAX 817
  • BAY 94-9027
  • BeneFIX
  • CSL627
  • Eloctate
  • FEIBA
  • Idelvion
  • Ixinity
  • Kogenate/Helixate and Kovaltry
  • N8-GP
  • N9-GP
  • NovoEight
  • NovoSeven
  • Nuwiq
  • Rixubis
  • Vonvendi
  • Xyntha/ReFacto
  • 主要調查手法

治療:血友病

  • 摘要整理
  • 主要調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢

流行病學:血友病

  • 摘要整理
  • 疾病的背景
  • 資訊來源·手法
  • 預測:血友病
  • 預測:類血友病病
  • 流行病學者的考察
  • 優勢與限制
  • 附錄

上市藥:血友病

  • 摘要整理
  • 產品概要
  • 後天性血友病的認證藥
  • 類血友病病的認證藥
  • 附錄
  • 產品簡介:Advate
  • 產品簡介:Adynovate
  • 產品簡介:Alprolix
  • 產品簡介:BeneFIX
  • 產品簡介:Eloctate
  • 產品簡介:FEIBA
  • 產品簡介:Idelvion
  • 產品簡介:Ixinity
  • 產品簡介:Kogenate FS
  • 產品簡介:NovoEight
  • 產品簡介:NovoSeven
  • 產品簡介:Rixubis
  • 產品簡介:Xyntha

開發平台:血友病

  • 摘要整理
  • 臨床開發平台概要
  • 標靶產品簡介
  • 臨床實驗設計
  • 產品簡介 (後期階段) :BAX 817
  • 產品簡介 (後期階段) :BAY 94-9027
  • 產品簡介 (後期階段) :CSL627
  • 產品簡介 (後期階段) :CSL689
  • 產品簡介 (後期階段) :Kovaltry
  • 產品簡介 (後期階段) :LR769
  • 產品簡介 (後期階段) :N8-GP
  • 產品簡介 (後期階段) :N9-GP
  • 產品簡介 (後期階段) :emicizumab

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12549

Disease Overview

Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Mainly men are affected by hemophilia A (factor VIII-deficient) and hemophilia B (factor IX-deficient), as is the case with most recessive, X-chromosomal disorders. In congenital hemophilia, the impaired production or functioning of one of the factors involved in the coagulation cascade is responsible for compromised blood coagulation, leading to uncontrolled and prolonged bleeding. The current standard of treatment for these patients is the replacement of the missing factor via clotting factor concentrate products. However, some patients develop antibodies against these therapies, called inhibitors, making treatment much more difficult.

Patients without hemophilia who develop inhibitors against clotting factor VIII or factor IX are diagnosed as having acquired hemophilia A or B, respectively. Although acquired hemophilia patients and congenital hemophilia patients with inhibitors share some similar traits and treatment options, acquired hemophilia affects men and women similarly, and has a distinct bleeding pattern.

Another disease associated with blood coagulation dysfunction is von Willebrand disease, which is caused by a deficiency in von Willebrand factor. Although von Willebrand disease is more common than hemophilia, it is relatively less severe, with most patients exhibiting mild disease that does not require regular treatment unless bleeding episodes caused by trauma or invasive procedures are uncontrollable.

Table of Contents

FORECAST: HEMOPHILIA

  • Executive Summary
  • Market Overview and Trends
  • Methodology and Market Definition
  • Advate
  • Adynovate
  • Alprolix
  • BAX 817
  • BAY 94-9027
  • BeneFIX
  • CSL627
  • Eloctate

FEIBA

  • Idelvion
  • Ixinity
  • Kogenate/Helixate and Kovaltry
  • N8-GP
  • N9-GP
  • NovoEight
  • NovoSeven
  • Nuwiq
  • Rixubis
  • Vonvendi
  • Xyntha/ReFacto
  • Primary Research Methodology

TREATMENT: HEMOPHILIA

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

EPIDEMIOLOGY: HEMOPHILIA

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast: Hemophilia
  • Forecast: Von Willebrand Disease
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix

MARKETED DRUGS: HEMOPHILIA

  • Executive Summary
  • Product Overview
  • Products Approved for Acquired Hemophilia
  • Products Approved for Von Willebrand Disease
  • Appendix
  • Product profile: Advate
  • Product profile: Adynovate
  • Product profile: Alprolix
  • Product profile: BeneFIX
  • Product profile: Eloctate
  • Product profile: FEIBA
  • Product profile: Idelvion
  • Product profile: Ixinity
  • Product profile: Kogenate FS
  • Product profile: NovoEight
  • Product profile: NovoSeven
  • Product profile: Rixubis
  • Product profile: Xyntha

PIPELINE: HEMOPHILIA

  • Executive Summary
  • Clinical Pipeline Overview
  • Target Product Profile
  • Clinical Trial Design
  • Product profile (late stage): BAX 817
  • Product profile (late stage): BAY 94-9027
  • Product profile (late stage): CSL627
  • Product profile (late stage): CSL689
  • Product profile (late stage): Kovaltry
  • Product profile (late stage): LR769
  • Product profile (late stage): N8-GP
  • Product profile (late stage): N9-GP
  • Product profile (late stage): emicizumab

APPENDIX

  • Appendix: Pipeline: Hemophilia

LIST OF FIGURES

  • Figure 1: Hemophilia sales across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 2: Hemophilia sales in the US, by type of therapy ($m), 2014-23
  • Figure 3: Hemophilia sales in Japan, by type of therapy ($m), 2014-23
  • Figure 4: Hemophilia sales in the five major EU markets, by type of therapy ($m), 2014-23
  • Figure 5: Sales of therapies for hemophilia A across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
  • Figure 6: Sales of therapies for hemophilia B across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
  • Figure 7: Sales of long-acting therapies for hemophilia A and hemophilia B across the US, Japan, and five major EU markets ($m), 2014-23
  • Figure 8: Hemophilia therapy sales from prophylactic and on-demand treatment, versus on-demand treatment only ($m), 2014-23
  • Figure 9: Sales of therapies for von Willebrand disease across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
  • Figure 10: Methodology flow
  • Figure 11: Advate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 12: Adynovate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 13: Alprolix sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 14: BAX 817 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 15: BAY 94-9027 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 16: BeneFIX sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 17: CSL627 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 18: Eloctate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 19: FEIBA sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 20: Idelvion sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 21: Ixinity sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 22: Combined sales for Kogenate and Kovaltry for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 23: N8-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 24: N9-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 25: NovoEight sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 26: NovoSeven sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 27: Nuwiq sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 28: Rixubis sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 29: Vonvendi sales for von Willebrand disease across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 30: Xyntha sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Figure 31: The intrinsic, extrinsic, and final common pathways of the clotting factor cascade
  • Figure 32: Percentage of hemophilia A and B patients with inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 33: Patient segmentation by treatment strategy for hemophilia A, B, and VWD patients in the US, Japan, and five major EU markets (%)
  • Figure 34: Uptake of prophylactic therapy strategies among hemophilia patients in the US, Japan, and five major EU markets (%)
  • Figure 35: Distribution of actively treated hemophilia patients by age across the US, Japan, and five major EU markets (%)
  • Figure 36: Uptake of prophylactic therapy versus on-demand therapy in VWD patients in the US, Japan, and five major EU markets (%)
  • Figure 37: Risk factors for inhibitor formation
  • Figure 38: Uptake and success of immune tolerance induction therapy in hemophilia A patients across the US, Japan, and five major EU markets (%)
  • Figure 39: Uptake and success of immune tolerance induction therapy in hemophilia B patients across the US, Japan, and five major EU markets (%)
  • Figure 40: Top three brands prescribed for the prophylactic treatment of hemophilia A without inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 41: Top three brands prescribed for the on-demand treatment of hemophilia A without inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 42: Top three brands prescribed for the prophylactic treatment of hemophilia B without inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 43: Top three brands prescribed for the on-demand treatment of hemophilia B without inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 44: Top three brands prescribed for the prophylactic treatment of hemophilia A with inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 45: Top three brands prescribed for the on-demand treatment of hemophilia A with inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 46: Top three brands prescribed for the prophylactic treatment of hemophilia B with inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 47: Top three brands prescribed for the on-demand treatment of hemophilia B with inhibitors across the US, Japan, and five major EU markets (%)
  • Figure 48: Top three brands prescribed for the prophylactic treatment of VWD across the US, Japan, and five major EU markets (%)
  • Figure 49: Top three brands prescribed for the on-demand treatment of VWD across the US, Japan, and five major EU markets (%)
  • Figure 50: Trend in diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 51: Change in diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 52: Trend in diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 53: Change in diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 54: Diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 55: Change in diagnosed prevalent cases of von Willebrand disease in the US, Japan and five major EU markets, by country, 2015-35
  • Figure 56: Advate for hemophilia A - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary of Advate in hemophilia A
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Advate in hemophilia A
  • Figure 59: Adynovate for hemophilia A - SWOT analysis
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Adynovate in hemophilia A
  • Figure 61: Datamonitor Healthcare's drug assessment summary of Adynovate in hemophilia A
  • Figure 62: Alprolix for hemophilia B - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Alprolix in hemophilia B
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Alprolix in hemophilia B
  • Figure 65: BeneFIX for hemophilia B - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of BeneFIX in hemophilia B
  • Figure 67: Datamonitor Healthcare's drug assessment summary of BeneFIX in hemophilia B
  • Figure 68: Eloctate for hemophilia A - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of Eloctate in hemophilia A
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Eloctate in hemophilia A
  • Figure 71: FEIBA for hemophilia with inhibitors - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of FEIBA in hemophilia with inhibitors
  • Figure 73: Datamonitor Healthcare's drug assessment summary of FEIBA in hemophilia with inhibitors
  • Figure 74: Idelvion for hemophilia B - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Idelvion in hemophilia B
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Idelvion in hemophilia B
  • Figure 77: Ixinity for hemophilia B - SWOT analysis
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Ixinity in hemophilia B
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Ixinity in hemophilia B
  • Figure 80: Kogenate FS for hemophilia A - SWOT analysis
  • Figure 81: Datamonitor Healthcare's drug assessment summary of Kogenate in hemophilia A
  • Figure 82: Datamonitor Healthcare's drug assessment summary of Kogenate in hemophilia A
  • Figure 83: NovoEight for hemophilia A - SWOT analysis
  • Figure 84: Datamonitor Healthcare's drug assessment summary of NovoEight in hemophilia A
  • Figure 85: Datamonitor Healthcare's drug assessment summary of NovoEight in hemophilia A
  • Figure 86: NovoSeven for hemophilia with inhibitors - SWOT analysis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of NovoSeven in hemophilia with inhibitors
  • Figure 88: Datamonitor Healthcare's drug assessment summary of NovoSeven in hemophilia with inhibitors
  • Figure 89: Rixubis for hemophilia B - SWOT analysis
  • Figure 90: Datamonitor Healthcare's drug assessment summary of Rixubis in hemophilia B
  • Figure 91: Datamonitor Healthcare's drug assessment summary of Rixubis in hemophilia B
  • Figure 92: Xyntha for hemophilia A - SWOT analysis
  • Figure 93: Datamonitor Healthcare's drug assessment summary of Xyntha in hemophilia A
  • Figure 94: Datamonitor Healthcare's drug assessment summary of Xyntha in hemophilia A
  • Figure 95: BAX 817 for hemophilia with inhibitors - SWOT analysis
  • Figure 96: Datamonitor Healthcare's drug assessment summary of BAX 817 in hemophilia with inhibitors
  • Figure 97: Datamonitor Healthcare's drug assessment summary of BAX 817 in hemophilia with inhibitors
  • Figure 98: BAY 94-9027 for hemophilia A - SWOT analysis
  • Figure 99: Datamonitor Healthcare's drug assessment summary of BAY 94-9027 in hemophilia A
  • Figure 100: Datamonitor Healthcare's drug assessment summary of BAY 94-9027 in hemophilia A
  • Figure 101: CSL627 for hemophilia A - SWOT analysis
  • Figure 102: Datamonitor Healthcare's drug assessment summary of CSL627 in hemophilia A
  • Figure 103: Datamonitor Healthcare's drug assessment summary of CSL627 in hemophilia A
  • Figure 104: CSL689 for hemophilia with inhibitors - SWOT analysis
  • Figure 105: Datamonitor Healthcare's drug assessment summary of CSL689 in hemophilia with inhibitors
  • Figure 106: Datamonitor Healthcare's drug assessment summary of CSL689 in hemophilia with inhibitors
  • Figure 107: Kovaltry for hemophilia A - SWOT analysis
  • Figure 108: Datamonitor Healthcare's drug assessment summary of Kovaltry in hemophilia A
  • Figure 109: Datamonitor Healthcare's drug assessment summary of Kovaltry in hemophilia A
  • Figure 110: LR769 for hemophilia with inhibitors - SWOT analysis
  • Figure 111: Datamonitor Healthcare's drug assessment summary of LR769 in hemophilia with inhibitors
  • Figure 112: Datamonitor Healthcare's drug assessment summary of LR769 in hemophilia with inhibitors
  • Figure 113: N8-GP for hemophilia A - SWOT analysis
  • Figure 114: Datamonitor Healthcare's drug assessment summary of N8-GP in hemophilia A
  • Figure 115: Datamonitor Healthcare's drug assessment summary of N8-GP in hemophilia A
  • Figure 116: N9-GP for hemophilia B - SWOT analysis
  • Figure 117: Datamonitor Healthcare's drug assessment summary of N9-GP in hemophilia B
  • Figure 118: Datamonitor Healthcare's drug assessment summary of N9-GP in hemophilia B
  • Figure 119: Emicizumab for hemophilia A - SWOT analysis
  • Figure 120: Datamonitor Healthcare's drug assessment summary of emicizumab in hemophilia A
  • Figure 121: Datamonitor Healthcare's drug assessment summary of emicizumab in hemophilia A

LIST OF TABLES

  • Table 1: Hemophilia sales across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 2: Hemophilia sales in the US, by type of therapy ($m), 2014-23
  • Table 3: Hemophilia sales in Japan, by type of therapy ($m), 2014-23
  • Table 4: Hemophilia sales in the five major EU markets, by type of therapy ($m), 2014-23
  • Table 5: Sales of therapies for hemophilia A across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
  • Table 6: Sales of therapies for hemophilia B across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
  • Table 7: Sales of long-acting therapies for hemophilia A and hemophilia B across the US, Japan, and five major EU markets ($m), 2014-23
  • Table 8: Hemophilia therapy sales from prophylactic and on-demand treatment, versus on-demand treatment only ($m), 2014-23
  • Table 9: Sales of therapies for von Willebrand disease across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
  • Table 10: Types of therapy and populations included in the hemophilia forecast
  • Table 11: Launch dates of key products for hemophilia across the US, Japan, and five major EU markets
  • Table 12: Price sources and calculations, by country
  • Table 13: Exchange rates used for calculating prices
  • Table 14: Frequency and severity of bleeding events in hemophilia
  • Table 15: Duration of treatment for mild, moderate, and severe bleeding events in hemophilia
  • Table 16: Advate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 17: Adynovate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 18: Alprolix sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 19: BAX 817 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 20: BAY 94-9027 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 21: BeneFIX sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 22: CSL627 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 23: Eloctate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 24: FEIBA sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 25: Idelvion sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 26: Ixinity sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 27: Combined sales for Kogenate and Kovaltry for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 28: N8-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 29: N9-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 30: NovoEight sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 31: NovoSeven sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 32: Nuwiq sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 33: Rixubis sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 34: Vonvendi sales for von Willebrand disease across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 35: Xyntha sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
  • Table 36: Hematologists surveyed for the hemophilia primary research study, 2013
  • Table 37: Hematologists, hematology internal medicine specialists, and pediatric hematologists surveyed for the hemophilia primary research study, 2016
  • Table 38: Sites and severity of bleeding in hemophilia A and B
  • Table 39: Most common bleeding symptoms of healthy individuals versus patients diagnosed with VWD
  • Table 40: Severity of hemophilia and related bleeding episodes
  • Table 41: Clinical and etiological features of von Willebrand types
  • Table 42: Historical overview and evaluation of the development of hemophilia therapies
  • Table 43: Commonly used guidelines for the treatment of hemophilia and VWD
  • Table 44: Patient segmentation by treatment strategy for hemophilia A patients without inhibitors in the US, Japan, and five major EU markets
  • Table 45: Patient segmentation by treatment strategy for hemophilia A patients with inhibitors in the US, Japan, and five major EU markets
  • Table 46: Patient segmentation by treatment strategy for hemophilia B patients without inhibitors in the US, Japan, and five major EU markets
  • Table 47: Patient segmentation by treatment strategy for hemophilia B patients with inhibitors in the US, Japan, and five major EU markets
  • Table 48: Patient segmentation by treatment strategy for VWD in the US, Japan, and five major EU markets
  • Table 49: Types of von Willebrand disease
  • Table 50: Severity of hemophilia and related bleeding episodes
  • Table 51: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 52: Age-specific diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015
  • Table 53: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by severity and country, 2015
  • Table 54: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by presence of inhibitors and country, 2015
  • Table 55: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by presence of co-morbid infectious disease and country, 2015
  • Table 56: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 57: Age-specific diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015
  • Table 58: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by severity and country, 2015
  • Table 59: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by presence of inhibitors and country, 2015
  • Table 60: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by presence of co-morbid infectious disease and country, 2015
  • Table 61: Diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 62: Age-specific diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015
  • Table 63: Gender-specific diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015
  • Table 64: Diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by type and country, 2015
  • Table 65: Key marketed drugs for hemophilia
  • Table 66: Obizur drug profile
  • Table 67: NovoSeven drug profile
  • Table 68: Alphanate drug profile
  • Table 69: Humate P drug profile
  • Table 70: Wilate drug profile
  • Table 71: Vonvendi drug profile
  • Table 72: Advate drug profile
  • Table 73: Advate pivotal trial data in hemophilia A
  • Table 74: Advate ongoing late-phase clinical trials in hemophilia A
  • Table 75: Adynovate drug profile
  • Table 76: Adynovate pivotal trial data in hemophilia A
  • Table 77: Adynovate ongoing late-phase clinical trials in hemophilia A
  • Table 78: Alprolix drug profile
  • Table 79: Alprolix pivotal trial data in hemophilia B
  • Table 80: Alprolix ongoing late-phase clinical trials in hemophilia B
  • Table 81: BeneFIX drug profile
  • Table 82: BeneFIX pivotal trial data in hemophilia B
  • Table 83: BeneFIX late-phase trial data in hemophilia B
  • Table 84: Eloctate drug profile
  • Table 85: Eloctate pivotal trial data in hemophilia A
  • Table 86: Eloctate ongoing late-phase clinical trials in hemophilia A
  • Table 87: FEIBA drug profile
  • Table 88: FEIBA pivotal trial data in hemophilia with inhibitors
  • Table 89: Idelvion drug profile
  • Table 90: Idelvion pivotal trial data in hemophilia B
  • Table 91: Idelvion ongoing late-phase clinical trials in hemophilia B
  • Table 92: Ixinity drug profile
  • Table 93: Ixinity pivotal trial data in hemophilia B
  • Table 94: Ixinity ongoing late-phase clinical trials in hemophilia B
  • Table 95: Kogenate FS drug profile
  • Table 96: Kogenate FS pivotal trial data in hemophilia A
  • Table 97: NovoEight drug profile
  • Table 98: NovoEight pivotal trial data in hemophilia A
  • Table 99: NovoEight ongoing late-phase clinical trials in hemophilia A
  • Table 100: NovoSeven drug profile
  • Table 101: NovoSeven pivotal trial data in hemophilia with inhibitors
  • Table 102: Rixubis drug profile
  • Table 103: Rixubis pivotal trial data in hemophilia B
  • Table 104: Rixubis late-phase trial data in hemophilia B
  • Table 105: Rixubis ongoing late-phase clinical trials in hemophilia B
  • Table 106: Xyntha drug profile
  • Table 107: Xyntha pivotal trial data in hemophilia A
  • Table 108: Xyntha ongoing late-phase clinical trials in hemophilia A
  • Table 109: Phase III pipeline products in development for hemophilia
  • Table 110: Gene therapies in early-phase development for hemophilia
  • Table 111: Eloctate drug profile
  • Table 112: Eloctate pivotal trial data in hemophilia A
  • Table 113: Alprolix drug profile
  • Table 114: Alprolix pivotal trial data in hemophilia B
  • Table 115: NovoSeven drug profile
  • Table 116: NovoSeven pivotal trial data in hemophilia with inhibitors
  • Table 117: BAX 817 drug profile
  • Table 118: BAX 817 Phase III data in hemophilia with inhibitors
  • Table 119: BAY 94-9027 drug profile
  • Table 120: BAY 94-9027 Phase III trials in hemophilia A
  • Table 121: CSL627 drug profile
  • Table 122: CSL627 Phase III data in hemophilia A
  • Table 123: CSL627 Phase III trials in hemophilia A
  • Table 124: CSL689 drug profile
  • Table 125: CSL689 Phase III trials in hemophilia with inhibitors
  • Table 126: Kovaltry drug profile
  • Table 127: Kovaltry Phase III data in hemophilia A
  • Table 128: LR769 drug profile
  • Table 129: LR769 Phase III trials in hemophilia with inhibitors
  • Table 130: N8-GP drug profile
  • Table 131: N8-GP Phase III data in hemophilia A
  • Table 132: N8-GP Phase III trials in hemophilia A
  • Table 133: N9-GP drug profile
  • Table 134: N9-GP Phase III data in hemophilia B
  • Table 135: N9-GP Phase III trials in hemophilia B
  • Table 136: Emicizumab drug profile
  • Table 137: Emicizumab Phase III trials in hemophilia A
Back to Top